Compare RDI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDI | AYTU |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | RDI | AYTU |
|---|---|---|
| Price | $1.08 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 38.2K | ★ 129.0K |
| Earning Date | 11-14-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $211,292,000.00 | $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.11 | N/A |
| 52 Week Low | $1.00 | $0.95 |
| 52 Week High | $1.78 | $3.07 |
| Indicator | RDI | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 49.33 |
| Support Level | $1.03 | $2.45 |
| Resistance Level | $1.15 | $2.77 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 35.71 | 34.52 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.